Skip to main content

NCBiotech News

  • In the six years since NCBiotech helped fund the recruitment of Ben Bahr, Ph.D., to head the University of North Carolina at Pembroke's molecular biology and biochemistry program, he has by all accounts earned a robust return on the state’s investment.
  • Five North Carolina companies will participate in pitch sessions during the 2015 BioMarine Business Convention in Wilmington Oct. 12-14.
  • Phoundry Pharmaceuticals, a peptide drug-discovery startup in Research Triangle Park, will be acquired by Boston-based Intarcia Therapeutics for an undisclosed price only seven months after Phoundry was spun out of GlaxoSmithKline.
  • Duke University spin-out TransEnterix, a publicly traded Morrisville-based medical device company, has purchased the surgical robotics division of Italian health care company Sofar in a cash and stock deal worth $99.8 million.
  • Durham development-stage drug company Scioderm, which announced at the end of August that it’s being acquired by Amicus Therapeutics of Cranbury, N.J., for $229 million, has also just notched a $400,000 grant from the U.S. Food and Drug Administration.
  • The FDA has given fast-track status to the second Cempra antibiotic product candidate in a month -- this time a fusidic acid compound named Taksta that is in stage-three clinical trials for the treatment of acute bacterial skin and skin structure infections.
  • Research Triangle Park-based medical diagnostics company BioMedomics has received a $222,950 grant from the National Institutes of Health to boost its development of a diagnostic test to aid in treating people with sickle cell disease.
  • High Point University held a groundbreaking ceremony for its $88 million Congdon School of Health Sciences and Fred Wilson School of Pharmacy – the fourth pharmacy school in the state.
  • Chaperone Therapeutics of Research Triangle Park has signed an exclusive, worldwide licensing agreement with Senhwa Biosciences of Taiwan for advanced small molecules that have therapeutic potential for diseases caused by protein misfolding.
  • Durham-based Scioderm will be acquired by Amicus Therapeutics of Cranbury, N.J., for $229 million, and the deal could grow to nearly $1 billion if Scioderm’s lead drug compound achieves certain clinical, regulatory and sales milestones.
  • Mayne Pharma,  a publicly traded pharmaceutical company based in Melbourne, Australia, has announced a three-year, $65 million, 110-employee expansion plan at the Greenville campus it established in 2012.
  • Novo Nordisk, a key member of North Carolina’s globally significant biomanufacturing landscape, is adding a projected $1.85 billion expansion and doubling its workforce of 700 at its 22-year-old Clayton campus in Johnston County.
  • Only two years after it raised $17.5 million in venture capital, AgBiome of Research Triangle Park announced today it has raised an additional $34.5 million to fund research and the projected launch of its first product, a natural fungicide for crops and turf grasses.
  • Cempra, a clinical-stage pharmaceutical company in Chapel Hill, has received fast track designation from the U.S. Food and Drug Administration for solithromycin, an antibiotic for treating community-acquired bacterial pneumonia.
  • In a two-day span, Raleigh's Sprout Pharmaceuticals won FDA approval to sell its drug Addyi -- and then sold itself for $1 billion in cash to Quebec pharma giant Valeant Pharmaceuticals.
  • Bioscience briefs with names making news
  • One year after it bought the Fresenius Kabi drug-manufacturing plant in North Raleigh, the Danish company Xellia Pharmaceuticals is expanding the site and relocating its North American headquarters to Raleigh from Grayslake, Ill.
  • G1 Therapeutics, a Research Triangle Park clinical-stage oncology company, has begun two clinical trials of a new therapy aimed at protecting the bone marrow and immune systems of patients undergoing chemotherapy for small-cell lung cancer.
  • The breakthrough $1 billion-plus Novartis cell culture vaccine factory in Holly Springs will be rebranded as Seqirus in October according to its new owner, CSL.
  • Chaperone Therapeutics of Research Triangle Park is teaming up with the nonprofit ALS Therapy Development Institute of Cambridge, Mass., to explore potential treatments for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease.


Subscribe to News & Events